Basic science

1O 

Harnessing innate immunity in cancer therapies: the example of Natural Killer Cell Engagers

Vivier, et al.

Conclusions

Tetrafunctional NKCE-IL2v thus constitutes a synthetic technological platform combining the induction of NK cell proliferation and effector functions without toxicity, supporting its clinical development for next-generation cancer immunotherapies.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1O.html.pdf

2O 

Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties

Li, et al.

Conclusions

Penpulimab, a PD-1 antibody with IgG1 isotype and Fc engineering, exhibits no Fc receptor mediated effector functions including ADCC, ADCP, and ADCR, and has robust T cell stimulating activity via blocking of PD-1.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/2O.html.pdf

3O 

Patient-derived micro-organospheres (MOS) recapitulate tumor microenvironment and heterogeneity for precision oncology

Din, et al.

Conclusions

Micro-organospheres are a rapid and scalable platform to preserve patient tumor microenvironment and heterogeneity. This platform will be useful for precision oncology, drug discovery, and immunotherapy development.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/3O.html.pdf

1800O 

Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

Á. Quintanal-Villalonga, et al.

Conclusions

Our findings provide the first comprehensive molecular characterization of LUSC transdifferentiation, suggesting putative drivers and promising therapeutic targets to constrain or prevent lineage plasticity in this setting.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1800O.html.pdf